FDA
-
-
-
-
-
-
-
4DMT partners with Otsuka for $85M upfront on Asia-Pacific drug deal
-
-
-
-
-
-
-
4DMT to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
4D Molecular Therapeutics (FDMT) PT Lowered to $63 at BMO Capital, 'uncertainty remains a lingering overhang until the PhIII readout'
-
-
-
-
-
-
-
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
-
-
-
-
-
-
-
4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023
-
-
-
-
-
-
-
4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
-
-
-
-
-
-
-
4D Molecular Therapeutics (FDMT) Reports Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial
-
323,731 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

